Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs

Author(s)
Ute Jungwirth, Dimitris N. Xanthos, Johannes Gojo, Anna Bytzek, Wilfried Körner, Petra Heffeter, Sergey Abramkin, Michael Jakupec, Christian Hartinger, Ursula Windberger, Mathea Sophia Galanski, Bernhard Keppler, Walter Berger
Abstract

Oxaliplatin is successfully used in systemic cancer therapy. However, resistance development and severe adverse effects are limiting factors for curative cancer treatment with oxaliplatin. The purpose of this study was to comparatively investigate in vitro and in vivo anticancer properties as well as the adverse effects of two methyl-substituted enantiomerically pure oxaliplatin analogs [[(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine]oxalatoplatinum(II) (KP1537), and [(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine]oxalatoplatinum(II) (KP1691)] and to evaluate the impact of stereoisomerism. Although the novel oxaliplatin analogs demonstrated in multiple aspects activities comparable with those of the parental compound, several key differences were discovered. The analogs were characterized by reduced vulnerability to resistance mechanisms such as p53 mutations, reduced dependence on immunogenic cell death induction, and distinctly attenuated adverse effects including weight loss and cold hyperalgesia. Stereoisomerism of the substituted methyl group had a complex and in some aspects even contradictory impact on drug accumulation and anticancer activity both in vitro and in vivo. To summarize, methyl-substituted oxaliplatin analogs harbor improved therapeutic characteristics including significantly reduced adverse effects. Hence, they might be promising metal-based anticancer drug candidates for further (pre)clinical evaluation.

Organisation(s)
Department of Inorganic Chemistry
External organisation(s)
Medizinische Universität Wien
Journal
Molecular Pharmacology
Volume
81
Pages
719-728
No. of pages
10
ISSN
0026-895X
DOI
https://doi.org/10.1124/mol.111.077321
Publication date
2012
Peer reviewed
Yes
Austrian Fields of Science 2012
104003 Inorganic chemistry, 301209 Pharmacy
Sustainable Development Goals
SDG 3 - Good Health and Well-being
Portal url
https://ucrisportal.univie.ac.at/en/publications/81ceffbd-19f2-4796-b65d-22dca3058118